NewTimeSpace丨BioRay Biopharmaceutical, China's Leading Autoimmune Disease Company, Files for Hong Kong IPO
BioRay Biopharmaceutical recently submitted its listing application to the Hong Kong Stock Exchange. According to Frost & Sullivan, the company has ranked first among Chinese pharmaceutical companies by autoimmune disease biologics revenue for two consecutive years since 2023. The prospectus shows it recorded revenue of RMB 1.623 billion and net profit of RMB 91 million in 2024, with a gross margin of 79.2%.
Zhejiang BioRay Biopharmaceutical Co., Ltd. (hereinafter referred to as "BioRay Biopharmaceutical") recently submitted its prospectus to the Hong Kong Stock Exchange, seeking a listing on the Main Board with Huatai International and J.P. Morgan as joint sponsors.
- FIRST CAP GP (01269.HK): Winding-Up Petition Hearing Adjourned to 1 February 2027, Scheme Meeting Hearing on 19 November
- GF SEC (01776.HK): RMB 370mn Advance Compensation Fund Set Up for Qingyue Technology Case
- SG MICRO (03661.HK): Subscribes RMB 200mn Fund Stake in Nanjing Yuanfeng Panmao with Own Funds
- DSBJ (02384.HK): HK offer closes, max price HK$93.8, net proceeds HK$10.52bn, listing Oct 28
- Going Global Weekly: Pharma Out-Licensing Deals Land in Succession as the A-Share Hong Kong Listing Pipeline Expands-20261023
